Ticker

IP and technology acquisition is expected to be highly accretive and to advance Lifeward's position as a diversified biomedical innovation company Will Expand Lifeward's portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfoli o Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and…

Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company

Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed's clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large,…

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical program Oramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrants Mark Grant, Lifeward CEO, with 25+ years…